Do analysts prefer XLO or WHWK?

Whitehawk Therapeutics has a consensus target price of $8.33, indicating a potential upside of 125.23%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Whitehawk Therapeutics is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Whitehawk Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media refer more to XLO or WHWK?

In the previous week, Xilio Therapeutics had 1 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 4 mentions for Xilio Therapeutics and 3 mentions for Whitehawk Therapeutics. Xilio Therapeutics' average media sentiment score of 0.00 equaled Whitehawk Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Whitehawk Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend XLO or CGEN?

Compugen has a consensus price target of $5.00, indicating a potential upside of 116.45%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Compugen 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media prefer XLO or CGEN?

In the previous week, Xilio Therapeutics had 3 more articles in the media than Compugen. MarketBeat recorded 4 mentions for Xilio Therapeutics and 1 mentions for Compugen. Xilio Therapeutics' average media sentiment score of 0.00 equaled Compugen'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compugen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ALXO or XLO?

ALX Oncology presently has a consensus target price of $4.60, indicating a potential upside of 277.05%. Given ALX Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe ALX Oncology is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ALXO or XLO?

In the previous week, ALX Oncology had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 5 mentions for ALX Oncology and 4 mentions for Xilio Therapeutics. ALX Oncology's average media sentiment score of 0.73 beat Xilio Therapeutics' score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PLX or XLO?

Protalix BioTherapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 342.80%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend KROS or XLO?

Keros Therapeutics currently has a consensus price target of $20.50, suggesting a potential upside of 80.46%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor KROS or XLO?

In the previous week, Keros Therapeutics had 3 more articles in the media than Xilio Therapeutics. MarketBeat recorded 7 mentions for Keros Therapeutics and 4 mentions for Xilio Therapeutics. Keros Therapeutics' average media sentiment score of 0.42 beat Xilio Therapeutics' score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Xilio Therapeutics (XLO) Competitors

$9.01 +0.10 (+1.12%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$8.98 -0.03 (-0.28%)

As of 10/2/2026 07:30 PM Eastern

Compare

XLO vs. WHWK, CGEN, ALXO, PLX, and KROS

Should you buy Xilio Therapeutics stock or one of its competitors? Xilio Therapeutics's main competitors and comparable companies include Whitehawk Therapeutics (WHWK), Compugen (CGEN), ALX Oncology (ALXO), Protalix BioTherapeutics (PLX), and Keros Therapeutics (KROS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xilio Therapeutics compare to Whitehawk Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Xilio Therapeutics had 1 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 4 mentions for Xilio Therapeutics and 3 mentions for Whitehawk Therapeutics. Xilio Therapeutics' average media sentiment score of 0.00 equaled Whitehawk Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Whitehawk Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Whitehawk Therapeutics has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.35	-$35.04M	-$1.64	N/A
Whitehawk Therapeutics	$7.14M	29.54	-$20.60M	-$1.12	N/A

Whitehawk Therapeutics has a consensus target price of $8.33, indicating a potential upside of 125.23%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Whitehawk Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Xilio Therapeutics has a beta of -0.15, indicating that its share price is 115% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Whitehawk Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Whitehawk Therapeutics' return on equity of -53.89% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Summary

Whitehawk Therapeutics beats Xilio Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Xilio Therapeutics compare to Compugen?

Xilio Therapeutics (NASDAQ:XLO) and Compugen (NASDAQ:CGEN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Compugen has a consensus price target of $5.00, indicating a potential upside of 116.45%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Compugen has a net margin of 47.56% compared to Xilio Therapeutics' net margin of -34.06%. Compugen's return on equity of 42.57% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
Compugen	47.56%	42.57%	26.13%

In the previous week, Xilio Therapeutics had 3 more articles in the media than Compugen. MarketBeat recorded 4 mentions for Xilio Therapeutics and 1 mentions for Compugen. Xilio Therapeutics' average media sentiment score of 0.00 equaled Compugen'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compugen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xilio Therapeutics has a beta of -0.15, indicating that its share price is 115% less volatile than the broader market. Comparatively, Compugen has a beta of 2.78, indicating that its share price is 178% more volatile than the broader market.

Compugen has higher revenue and earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.35	-$35.04M	-$1.64	N/A
Compugen	$72.76M	3.00	$35.34M	$0.38	6.08

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Compugen beats Xilio Therapeutics on 14 of the 16 factors compared between the two stocks.

How does Xilio Therapeutics compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Xilio Therapeutics has higher revenue and earnings than ALX Oncology. Xilio Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
Xilio Therapeutics	$43.77M	1.35	-$35.04M	-$1.64	N/A

ALX Oncology presently has a consensus target price of $4.60, indicating a potential upside of 277.05%. Given ALX Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe ALX Oncology is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ALX Oncology has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Xilio Therapeutics' return on equity of -71.99% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
Xilio Therapeutics	-34.06%	-71.99%	-20.43%

In the previous week, ALX Oncology had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 5 mentions for ALX Oncology and 4 mentions for Xilio Therapeutics. ALX Oncology's average media sentiment score of 0.73 beat Xilio Therapeutics' score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 12.4% of ALX Oncology shares are owned by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ALX Oncology has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.15, meaning that its share price is 115% less volatile than the broader market.

Summary

ALX Oncology beats Xilio Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Xilio Therapeutics compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Protalix BioTherapeutics has higher revenue and earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.71	$8.31M	$0.23	11.78
Xilio Therapeutics	$43.77M	1.35	-$35.04M	-$1.64	N/A

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Protalix BioTherapeutics has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.15, meaning that its stock price is 115% less volatile than the broader market.

In the previous week, Xilio Therapeutics had 4 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for Xilio Therapeutics and 0 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 0.00 equaled Xilio Therapeutics'average media sentiment score.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
Xilio Therapeutics	Neutral

Protalix BioTherapeutics has a net margin of -21.03% compared to Xilio Therapeutics' net margin of -34.06%. Protalix BioTherapeutics' return on equity of -30.89% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Xilio Therapeutics	-34.06%	-71.99%	-20.43%

Protalix BioTherapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 342.80%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Protalix BioTherapeutics beats Xilio Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Xilio Therapeutics compare to Keros Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

In the previous week, Keros Therapeutics had 3 more articles in the media than Xilio Therapeutics. MarketBeat recorded 7 mentions for Keros Therapeutics and 4 mentions for Xilio Therapeutics. Keros Therapeutics' average media sentiment score of 0.42 beat Xilio Therapeutics' score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xilio Therapeutics has a net margin of -34.06% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.40%	-19.79%
Xilio Therapeutics	-34.06%	-71.99%	-20.43%

Keros Therapeutics currently has a consensus price target of $20.50, suggesting a potential upside of 80.46%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 12.6% of Keros Therapeutics shares are owned by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Keros Therapeutics has higher revenue and earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.92	$87.01M	-$3.70	N/A
Xilio Therapeutics	$43.77M	1.35	-$35.04M	-$1.64	N/A

Keros Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.15, indicating that its share price is 115% less volatile than the broader market.

Summary

Keros Therapeutics beats Xilio Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Xilio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XLO vs. The Competition

Export

Metric	Xilio Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$59.29M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-5.49	13.06	275.66	26.04
Price / Sales	1.35	1,295.73	609.44	91.76
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	1.23	16.63	10.93	6.31
Net Income	-$35.04M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-0.33%	-2.99%	-2.00%	-1.66%
1 Month Performance	-0.11%	-10.60%	-6.15%	-4.50%
1 Year Performance	-21.32%	19.44%	7.44%	2.06%

Xilio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XLO Xilio Therapeutics	0.0502 of 5 stars	$9.01 +1.1%	N/A	-19.6%	$59.29M	$43.77M	N/A	76	News Coverage
WHWK Whitehawk Therapeutics	2.3741 of 5 stars	$4.04 flat	$8.20 +103.0%	+90.7%	$230.32M	$7.14M	N/A	23	News Coverage Positive News Analyst Forecast
CGEN Compugen	2.8637 of 5 stars	$2.49 +2.5%	$5.00 +100.8%	+31.3%	$230.24M	$72.76M	6.55	75
ALXO ALX Oncology	3.117 of 5 stars	$1.60 -3.6%	$4.60 +187.5%	-36.1%	$229.54M	N/A	N/A	48
PLX Protalix BioTherapeutics	2.4712 of 5 stars	$2.84 +3.3%	$12.00 +322.5%	+15.8%	$228.82M	$80.62M	N/A	226

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XLO) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xilio Therapeutics (XLO) Competitors

XLO vs. WHWK, CGEN, ALXO, PLX, and KROS

How does Xilio Therapeutics compare to Whitehawk Therapeutics?

Summary

How does Xilio Therapeutics compare to Compugen?

Summary

How does Xilio Therapeutics compare to ALX Oncology?

Summary

How does Xilio Therapeutics compare to Protalix BioTherapeutics?

Summary

How does Xilio Therapeutics compare to Keros Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xilio Therapeutics (XLO) Competitors

XLO vs. WHWK, CGEN, ALXO, PLX, and KROS

How does Xilio Therapeutics compare to Whitehawk Therapeutics?

Does the media refer more to XLO or WHWK?

Do insiders and institutionals believe in XLO or WHWK?

Which has stronger earnings and valuation, XLO or WHWK?

Do analysts prefer XLO or WHWK?

Which has more risk and volatility, XLO or WHWK?

Is XLO or WHWK more profitable?

Summary

How does Xilio Therapeutics compare to Compugen?

Do analysts recommend XLO or CGEN?

Is XLO or CGEN more profitable?

Does the media prefer XLO or CGEN?

Which has more risk and volatility, XLO or CGEN?

Which has higher earnings and valuation, XLO or CGEN?

Do insiders & institutionals have more ownership in XLO or CGEN?

Summary

How does Xilio Therapeutics compare to ALX Oncology?

Which has stronger valuation & earnings, ALXO or XLO?

Do analysts prefer ALXO or XLO?

Is ALXO or XLO more profitable?

Does the media favor ALXO or XLO?

Do institutionals and insiders have more ownership in ALXO or XLO?

Which has more volatility & risk, ALXO or XLO?

Summary

How does Xilio Therapeutics compare to Protalix BioTherapeutics?

Which has better valuation & earnings, PLX or XLO?

Do institutionals & insiders believe in PLX or XLO?

Which has more volatility and risk, PLX or XLO?

Does the media favor PLX or XLO?

Is PLX or XLO more profitable?

Do analysts rate PLX or XLO?

Summary

How does Xilio Therapeutics compare to Keros Therapeutics?

Does the media favor KROS or XLO?

Is KROS or XLO more profitable?

Do analysts recommend KROS or XLO?

Do institutionals and insiders hold more shares of KROS or XLO?

Which has higher earnings & valuation, KROS or XLO?

Which has more risk and volatility, KROS or XLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools